Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Licenses MicroRNA IP From Rockefeller University

NEW YORK (GenomeWeb News) – Asuragen licensed microRNA sequences from Rockefeller University to develop early cancer detection tools, the company said today.
 
Under the semi-exclusive agreement, Asuragen will have access to microRNAs identified by a group led by Thomas Tuschl. These microRNAs are involved with human diseases like diabetes and cancer.
 
Financial details were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.